LUNA18 (Paluratide) is an orally bioavailable 11-mer cyclic peptide KRAS inhibitor for the intracellular tough target RAS. It binds to KRASG12D with a kd of 0.043 nM and blocks KRASG12D–SOS1 interaction at IC50 of < 2.2 nM. It also exhibits antiproliferative activity in KRAS-mutant cancer cell lines with an IC50 of 1.4 nM in AsPC-1 pancreatic cancer cells.